Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05495269 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)
A Phase 2 study, sponsored by Qlaris Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT05495269: Completed Phase 2 study, sponsored by Qlaris Bio.
NCT05495269 is a Phase 2 study that has completed, run by Qlaris Bio. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05495269, a Phase 2 study, has completed, sponsored by Qlaris Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Open-label study of an investigational product (IP), QLS-101, with 28-day every morning (QAM) dosing to both eyes (OU) in adolescents with SWS who have clinical evidence of glaucoma and/or ocular hypertension (OHT) related to SWS elevated EVP in at least one eye.
Primary Outcome
Incidence of ocular treatment emergent adverse events (TEAEs)
Interventions
- DRUG QLS-101 ophthalmic solution, 2.0 %
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-11-23 |
| Est. Completion | 2023-03-20 |
| Phase | Phase 2 |
What the finished NCT05495269 record still lists
NCT05495269 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which QLS-101 ophthalmic solution, 2.0 % is the first listed.
NCT05495269 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05495269 about?
NCT05495269 is a clinical study titled "Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)". Open-label study of an investigational product (IP), QLS-101, with 28-day every morning (QAM) dosing to both eyes (OU) in adolescents with SWS who have clinical evidence of glaucoma and/or ocular hypertension (OHT) related to SWS elevated EVP in at least one eye.
What is the current status of trial NCT05495269?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2022-11-23. Estimated completion is 2023-03-20.
What interventions are being tested in trial NCT05495269?
The interventions under investigation include: QLS-101 ophthalmic solution, 2.0 % (DRUG).
Who is sponsoring clinical trial NCT05495269?
This trial is sponsored by Qlaris Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05495269's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI